Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001
Table: Anges - 9-MTH group results
Table: Anges -2025 group forecast
Table: Anges - 6-MTH group results
Table: Anges -Q1 group results
Table: Anges -2024 group results
Table: Anges -2024 parent results
Table: Anges -Q1 group results
Table: Anges -2024 group forecast
Table: Anges -2023 group results
Table: Anges -2023 parent results
Table: Anges -2023 group results
Table: Anges -2023 parent results
Brief: Vasomune And Anges Announce Drug Candidate Av-001 Receives Positive Recommendation From The IDSMB
Table: Anges - 9-MTH group results
Table: Anges - 6-MTH group results